Semaglutide
Also sold as Ozempic, Wegovy, Rybelsus
About
About Semaglutide
A synthetic glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide mimics the incretin hormone GLP-1 to stimulate glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying. The compound also acts on hypothalamic receptors to reduce appetite and food intake. Primary clinical applications include the management of type 2 diabetes mellitus and chronic weight management in individuals with obesity or overweight with weight-related comorbidities.
Science
Mechanism of Action
Semaglutide binds to and activates the GLP-1 receptor (GLP-1R), a GPCR expressed in the pancreas, brain, gut, heart, and kidneys. In the pancreas, GLP-1R activation stimulates glucose-dependent insulin secretion and suppresses glucagon. In the brain (hypothalamus and brainstem), it reduces appetite and increases satiety. Gastric emptying is slowed, contributing to reduced caloric intake. The net effect is significant weight loss and improved glycemic control.
Dosing
Typical Protocol
Week 1–4: 0.25 mg subcutaneously once weekly. Week 5–8: 0.5 mg once weekly. Week 9–12: 1.0 mg once weekly. Maintenance: 1.0–2.4 mg once weekly (titrate based on tolerability and response). Contraindications include personal/family history of MEN2, medullary thyroid carcinoma, or pancreatitis.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This is an FDA-approved finished drug. Now that its FDA-declared shortage has resolved, federal law no longer lets compounding pharmacies make bulk copies of it under Section 503B. Compounding under Section 503A stays possible only for a narrow, individually documented clinical need, such as a verified allergy to an inactive ingredient in the approved product, or a strength or dosage form the manufacturer does not make. Cost savings or convenience are not, by themselves, a lawful basis for compounding it. The FDA-approved product from a licensed pharmacy is the default; a compounded version should carry a clear, patient-specific clinical rationale.
Off the FDA drug shortage list. Verified June 1, 2026 via the openFDA drug shortage database.
FDA declared the shortage resolved on February 21, 2025. Enforcement discretion for compounding ended April 22, 2025 under Section 503A and May 22, 2025 under Section 503B. FDA announcement.
Evidence
Evidence Tier
Supported by the clinical trial data required for FDA approval, representing the highest evidence bar. Safety and efficacy have been established in multiple phases of human clinical trials.
Compare verified providers offering Semaglutide
All 28 audited providers, ranked by Vial Check by default. Click any column to sort.
Compound comparisons
Compare Semaglutide
Semaglutide set against other compounds people weigh it against.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.